Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Pimasertib (Primary) ; Temsirolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono; Merck KGaA
- 10 Jun 2017 Biomarkers information updated
- 13 Feb 2017 Results assessing maximum tolerated dose, recommended phase 2 dose of pimasertib in combination with temsirolimus as well as safety and pharmacokinetics published in the Investigational New Drugs.
- 28 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.